News

Bukwang Pharma and its fully owned subsidiary Contera Pharma are pleased to announce that the investigational medical product, JM-010 has been dosed to the first patients with Parkinson’s disease suffering from moderate to severe levodopa-induced dyskinesia. The Phase IIa/Proof-of-Concept study is a randomized, double-blind, placebo-controlled, 2-way crossover study, which will assess the efficacy, safety/tolerability and […]

Solural Pharma and Contera Pharma have in collaboration with Ernst Moritz Arndt University Greifswald, Germany and Erweka GmbH, Germany been awarded a Eurostar grant to support a project to develop new treatments of morning akinesia associated with Parkinson’s disease (PD). Parkinson’s disease, which affects 1 in 100 people over the age of 60, is primarily […]

Contera Pharma announces acquisition by Korean Bukwang Pharmaceutical JM-010 to enter global development for L-DOPA induced dyskinesia Contera Pharma (Copenhagen, Denmark) is pleased to announce that Bukwang Pharmaceutical (Seoul, Korea) has acquired 100% of Contera Pharma from its current shareholders. The shareholders received an undisclosed upfront payment and are entitled to future contingent and royalty […]

Concit Pharma has changed its corporate name to Contera Pharma, effective from 19.11.2013. As of 19.11.2013 Don deBethizy is appointed chairman of the board. Don is the former CEO of Targacept, Inc a public biotech company discovering and developing novel small molecules targeting serious CNS disorders. Don will help the company to explore financing opportunities […]

Concit Pharma paricipated in the Danish Life Sciences Investor Forum in New York on 30.09.2013 to 02.10.2013.

On July 1st Concit Pharma received approval of protocol for the Phase IIa study in L-DOPA induced dyskinesia. The approval is an important milestone and strongly supports Concit Pharma’s development plans.